In New Suit, Life Tech Claims Illumina's Genome Analyzer Infringes Amplification IP | GenomeWeb

This article has been updated to include a statement from Illumina.

NEW YORK (GenomeWeb News) - Life Technologies and several co-plaintiffs this week filed suit against Illumina for allegedly infringing three DNA-amplification patents.

The suit, filed in the US District Court for the District of Delaware, claims that Illumina and Solexa, which Illumina acquired in 2007, infringe US Patent Nos. 5,616,478; 5,989,698; and 6,001,568. All three patents relate to amplifying nucleic acids in a solid medium.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Sep
24
Sponsored by
Personalis

This online seminar will outline a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. 

Oct
07
Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.